These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 26743169)
1. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169 [TBL] [Abstract][Full Text] [Related]
2. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One? Vaduganathan M; Bhatt DL Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743 [No Abstract] [Full Text] [Related]
3. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861 [TBL] [Abstract][Full Text] [Related]
4. GLS-409, an Antagonist of Both P2Y Smolensky Koganov E; Michelson AD; Yanachkov IB; Yanachkova MI; Wright GE; Przyklenk K; Frelinger AL Sci Rep; 2018 Sep; 8(1):14529. PubMed ID: 30266987 [TBL] [Abstract][Full Text] [Related]
5. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors? Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036 [TBL] [Abstract][Full Text] [Related]
6. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364 [TBL] [Abstract][Full Text] [Related]
7. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor. Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131 [TBL] [Abstract][Full Text] [Related]
9. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man. Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765 [TBL] [Abstract][Full Text] [Related]
10. Can the PFA-100 be modified to detect P2Y12 inhibition? Pidcock M; Harrison P J Thromb Haemost; 2006 Jun; 4(6):1424-6. PubMed ID: 16706997 [No Abstract] [Full Text] [Related]
11. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism. Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. Cattaneo M; Lecchi A J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538 [TBL] [Abstract][Full Text] [Related]
14. Antiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphate. Chang H; Yanachkov IB; Dix EJ; Yanachkova M; Li Y; Barnard MR; Wright GE; Michelson AD; Frelinger AL PLoS One; 2014; 9(4):e94780. PubMed ID: 24722456 [TBL] [Abstract][Full Text] [Related]
15. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S Platelets; 2011; 22(7):504-15. PubMed ID: 21591981 [TBL] [Abstract][Full Text] [Related]
16. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084 [TBL] [Abstract][Full Text] [Related]
17. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro. Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514 [TBL] [Abstract][Full Text] [Related]
18. Platelets Express Activated P2Y Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879 [TBL] [Abstract][Full Text] [Related]
19. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949 [TBL] [Abstract][Full Text] [Related]
20. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]